References
1. Dasari A, Shen C, Halperin D, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA oncology 2017;3:1335–1342.
2. Hurtado-Pardo L, Breeze CE, Cienfuegos JA, et al. Comparison of phenotypes and outcomes following resection of incidental versus symptomatic pancreatic neuroendocrine tumors. Rev Esp Enferm Dig 2021. doi:10.17235/reed.2021.8096/2021. Online ahead of print
3. Inzani F, Petrone G, Rindi G. The New World Health Organization Classification for Pancreatic Neuroendocrine Neoplasia. Endocrinol Metab Clin Nort Am 2018;47:463–470.
4. Howe JR, Merchant NB, Conrad C, et al. The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors. Pancreas 2020;49:1–33.
5. Falconi M, Eriksson B, Kaltsas G, et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology 2016;103:153–71.
6. Aziz H, Howe JR, Pawlik TM. Surgery vs Observation for Patients With Small Pancreatic Neuroendocrine Tumors. JAMA surgery 2021;156:412-413
7. De Rooij T, Klompmaker S, Hilal MA, Kendrick ML, Busch OR, Besselink MG. Laparoscopic pancreatic surgery for benign and malignant disease. Nat Rev Gastroenterol & Hepatol 2016;13:227–238.
8. Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 2018;31:1770–1786.
9. Cienfuegos JA, Salguero J, Núñez-Córdoba JM, et al. Short- and long-term outcomes of laparoscopic organ-sparing resection in pancreatic neuroendocrine tumors: a single-center experience. Surg Endosc 2017;31:3847–3857.
10. Hurtado-Pardo L, Cienfuegos JA, Antoñanzas J, et al. Incidental lesions of the pancreas. A clinicopathological study of 100 cases surgically treated. Revi Esp Enferm Dig 2020;112:85-89.
11. Barturen Á. Incidental pancreatic lesions - A diagnostic and management challenge. Rev Esp Enferm Dig: 2020;112:83–84.
12. Cloyd JM, Poultsides GA. The Landmark Series: Pancreatic Neuroendocrine Tumors. Ann Surg Oncol 2021;28:1039–1049.
13. Sadot E, Reidy-Lagunes DL, Tang LH, et al. Observation versus Resection for Small Asymptomatic Pancreatic Neuroendocrine Tumors: A Matched Case–Control Study. Ann Surg Oncol 2016;23:1361–1370.
14. Lee LC, Grant CS, Salomao DR, et al. Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management Surgery 2012;152:965–974.
15. Finkelstein P, Sharma R, Picado O, et al. Pancreatic Neuroendocrine Tumors (panNETs): Analysis of Overall Survival of Nonsurgical Management Versus Surgical Resection. J Gastrointest Surg 2017;21:855–866.
16. Mintziras I, Keck T, Werner J, et al. Implementation of Current ENETS Guidelines for Surgery of Small (≤2 cm) Pancreatic Neuroendocrine Neoplasms in the German Surgical Community: An Analysis of the Prospective DGAV StuDoQ|Pancreas Registry. World J Surg 2019;43:175–182
17. Partelli S, Ramage JK, Massironi S, et al. Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≤2 cm: Study Protocol for a Prospective Observational Study. Front. Med. 2020;7:1–8.doi: 10.3389/fmed.2020.598438.
18. Heidsma CM, Engelsman AF, van Dieren S, et al. Watchful waiting for small non-functional pancreatic neuroendocrine tumours: nationwide prospective cohort study (PANDORA). Br J Surg 2021;108:888–891.
19. Assi HA, Mukherjee S, Kunz PL, et al. Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database. The oncologist 2020;25:e276–e283.
20. Bettini R, Partelli S, Boninsegna L, et al. Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. Surgery 2011;150:75–82.
21. Sallinen VJ, Le Large TTY, Tieftrunk E, et al. Prognosis of sporadic resected small (≤2 cm) nonfunctional pancreatic neuroendocrine tumors – a multi-institutional study. HPB 2018;20:251–259.
22. Hashim YM, Trinkaus KM, Linehan DC, et al. Regional lymphadenectomy is indicated in the surgical treatment of Pancreatic Neuroendocrine Tumors (PNETs). Ann Surg 2014;259:197–203.
23. Sharpe SM, In H, Winchester DJ, Talamonti MS, Baker MS. Surgical Resection Provides an Overall Survival Benefit for Patients with Small Pancreatic Neuroendocrine Tumors. J Gastrointest Surg 2014;19:117–123.
24. Partelli S, Cirocchi R, Crippa S, et al. Systematic review of active surveillance versus surgical management of asymptomatic small non-functioning pancreatic neuroendocrine neoplasms. Bri J Surg 2017;104:34–41.
25. Genç CG, Jilesen AP, Partelli S, et al. A New Scoring System to Predict Recurrent Disease in Grade 1 and 2 Nonfunctional Pancreatic Neuroendocrine Tumors. Ann Surg 2018;267:1148–1154.